Amatuximab  (Synonyms: 阿麦妥单抗; MORab-009)

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

Amatuximab (MORAb-009) 是一种鼠-人嵌合单克隆抗体，对 MSLN 具有选择性亲和力。在体外，Amatuximab 可引发针对表达间皮素的肿瘤细胞系的抗体依赖性细胞毒性 (ADCC)，并抑制间皮素阳性肿瘤细胞与表达 CA125 的肿瘤细胞的异型细胞粘附^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

在肿瘤异种移植研究中，与单独使用阿妥昔单抗或化疗相比，使用阿妥昔单抗和化疗联合处理可更大程度地减少表达间皮素的肿瘤的生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

931402-35-6

液体

Colorless to light yellow

阿麦妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Amatuximab on AHC2 biosensor, can bind Mesothelin Protein, Human (303a.a, HEK293, His, HY-P70148) with an affinity constant of 6.469E-10 M as determined in BLI assay.

• [1]. Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936.  [Content Brief]

  [2]. Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8.  [Content Brief]